RenovoRx, Inc. (RNXT)
| Market Cap | 23.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.09M |
| Shares Out | 9.10M |
| EPS (ttm) | -0.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 217 |
| Open | 2.68 |
| Previous Close | 2.63 |
| Day's Range | 2.68 - 2.68 |
| 52-Week Range | 1.50 - 5.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.20 (+280.6%) |
| Earnings Date | n/a |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for RNXT stock is "Buy." The 12-month stock price forecast is $10.2, which is an increase of 280.60% from the latest price.
News
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive O...
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokine...
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January ...
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance o...
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...
RenovoRx Reports Third Quarter 2022 Financial Results
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
LOS ALTOS, Calif.
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...
RenovoRx Reports Second Quarter 2022 Financial Results
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...
RenovoRx Appoints James Ahlers as Chief Financial Officer
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Fi...
RenovoRx Launches “The RenovoRx Story” Video Series
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a n...
RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that they will host a webinar highlighting thei...
RenovoRx to Participate in the University of Cambridge's Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway to Tran...
RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform's Potential Utility for the Treatment of Bile Duct Cancer
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will pres...
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management's part...
RenovoRx Reports First Quarter 2022 Financial Results
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial ...
RenovoRx Sponsors Pancreatic Cancer Action Network's PurpleStride Event to End Pancreatic Cancer
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, announced today it will join the ...
RenovoRx Reports Full Year 2021 Financial Results
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial ...
RenovoRx to Participate in March 2022 Investor Conferences
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership's ...
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University's New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
NEW YORK & LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enroll...
RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the “Delivering Therapy...
RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Ga...